Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$32.54 -2.04%

-$1.24 today

Market cap
$933.51M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.86M

Average 1.00M

Income Statement

Follow revenue through to earnings.

Revenue

$55.23M

FY 2025 · Annual

-43.9% YoY

Operating Income

-$130.77M

FY 2025 · Annual

Net Income

-$164.08M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

NKTR Earnings Waterfall · TTM

NASDAQ:NKTR · Revenue to Net Income

Key Ratios

EPS$-6.70
Gross Margin99.2%
Net Margin-320.3%
P/E Ratio-9.4
P/S Ratio124.7

Analysis

$54.6M of revenue converted into -$157.1M of net income for the selected period. Gross margin is 99.2% and net margin is -320.3%, showing how much revenue survives after costs and taxes. EPS is $-6.70, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 13, 2026
8-KCurrent reportNov 13, 2026
8-KCurrent reportNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
S-8S-8 filingOct 20, 2026

How much revenue does NKTR generate?

Nektar Therapeutics (NKTR) reported $55.23M of revenue in fiscal 2025.

Is NKTR profitable?

Nektar Therapeutics (NKTR) reported -$164.08M of net income, with a net margin of -297.1%.